Wedbush Downgrades Fate Therapeutics (FATE) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts FATE Hot Sheet
Price: $2.07 --0%
Rating Summary:
11 Buy, 13 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 11 | New: 12
Rating Summary:
11 Buy, 13 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 11 | New: 12
Join SI Premium – FREE
Wedbush analyst David Nierengarten downgraded Fate Therapeutics (NASDAQ: FATE) from Outperform to Neutral with a price target of $88.00.
For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.
Shares of Fate Therapeutics closed at $86.27 yesterday.
You May Also Be Interested In
- Oppenheimer Downgrades Enphase Energy (ENPH) to Perform, 'Core Business Recovery Not Materializing'
- UBS Downgrades EMS-Chemie Holding AG (EMSN:SW) to Neutral
- Jefferies Downgrades The Simply Goods Group (SMPL) to Hold
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
